

Neurotech

18 November 2019

Results of Meeting

Neurotech International Limited (ASX: NTI) today held its 2019 Annual General Meeting at Suite 5 CPC, 145 Stirling Highway, Nedlands WA 6009.

All Resolutions were determined by poll.

The outcome of each resolution put to shareholders at the AGM is set out in Annexure A.

For further information please contact:

Erlyn Dale

Company Secretary

Email: erlyn@azc.com.au

Phone: 0424 676 671

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism.

Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>

<http://www.mentetech.com>

Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway

Nedlands, Western Australia 6009

www.neurotechinternational.com

For personal use only

Disclosure of Proxy Votes

Neurotech International Limited

Annual General Meeting

Monday, 18 November 2019

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results		
		For	Against	Abstain	Discretionary	For	Against	Abstain
01 Adoption of the Remuneration Report	24,376,861	23,505,559	363,595	9,087,256	507,707	24,013,266	363,595	9,087,256
02 Re-election of Dr David Cantor as a Director	25,821,261	24,967,865	7,783	7,642,856	845,613	25,813,478	7,783	7,642,856
03 Election of Mr Winton Willesee as a Director	25,964,118	25,110,722	7,783	7,499,999	845,613	25,956,335	7,783	7,499,999
04 Election of Mr Mark Davies as a Director	25,964,118	25,110,722	7,783	7,499,999	845,613	25,956,335	7,783	7,499,999
05 Approval of Additional 10% Placement Facility	25,964,118	24,959,910	158,595	7,499,999	845,613	25,805,523	158,595	7,499,999
06 Approval for grant of Options to a Director – Mr Winton Willesee	25,606,212	25,033,472	65,033	7,857,905	507,707	25,541,179	65,033	7,857,905
07 Approval for grant of Options to a Director – Mr Mark Davies	25,944,118	25,033,472	65,033	7,519,999	845,613	25,879,085	65,033	7,519,999
08 Approval for grant of Options to a Director – Dr David Cantor	25,801,261	24,890,615	65,033	7,662,856	845,613	25,736,228	65,033	7,662,856
09 Approval to grant Options to Mr Peter Griffiths under Consultancy Services Agreement	18,671,740	17,590,282	215,845	14,792,377	865,613	18,455,895	215,845	14,792,377
10 Approval to issue Convertible Notes	25,964,118	24,924,910	193,595	7,499,999	845,613	25,432,617	193,595	7,837,905
11 Ratification of Shares issued on conversion of Convertible Loan	25,964,118	24,924,910	193,595	7,499,999	845,613	25,432,617	193,595	7,837,905
12 Approval to grant Conversion Options to holders of Shares issued on conversion of Convertible Loan	25,964,118	24,904,910	193,595	7,499,999	865,613	25,432,617	193,595	7,837,905
13 Approval to issue Options to Max Capital	25,944,118	24,752,660	345,845	7,519,999	845,613	25,598,273	345,845	7,519,999
14 Approval to amend Company Constitution	25,964,118	24,817,693	300,812	7,499,999	845,613	25,663,306	300,812	7,499,999